PCV chemotherapy for recurrent glioblastoma multiforme.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 11148250.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status > or = 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Glioblastoma
- Lomustine
- Procarbazine
- Vincristine